Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price hit a new 52-week high on Wednesday . The stock traded as high as C$0.10 and last traded at C$0.08, with a volume of 155000 shares. The stock had previously closed at C$0.09.
Hemostemix Stock Performance
The business has a 50 day simple moving average of C$0.09 and a 200-day simple moving average of C$0.06. The firm has a market capitalization of C$6.97 million, a price-to-earnings ratio of -4.50 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- 3 Warren Buffett Stocks to Buy Now
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What is a Stock Market Index and How Do You Use Them?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- How to Use the MarketBeat Stock Screener
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
